2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

506. Bone Marrow Microenvironment: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Hemoglobinopathies, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4914 Hepatocyte growth factor promotes stromal cell expansion and autophagy-linked remodeling of the hematopoietic niche

Annika Chura, MS, Wantong Li, MS2, Konur Oyman, MSc3, Shelby Cabrera4, Xavier Emmett Vesco5, Victoria Wang, MD, PhD6, Antonio Perez-Castro, PhD7, Charalambos Andreadis, MD, MS8, Hay-Oak Park, PhD9, Emily Curran, MD10, Christopher C Oakes, PhD11, Bradley Blaser, MD12
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 University of California, San Francisco, San Francisco, California, United States
7 The Ohio State University, Columbus, Ohio, United States
8 University of California, San Francisco, San Francisco, California, United States
9 The Ohio State University, Columbus, Ohio, United States
10 University of Cincinnati, Cincinnati, Ohio, United States
11 The Ohio State University, Columbus, Ohio, United States
12 The Ohio State University, Columbus, Ohio, United States

A hepatocyte growth factor (HGF)-specific antibody, ficlatuzumab, has demonstrated safety and preliminary efficacy in relapsed/refractory AML. ScRNA-seq analysis of patient blood samples revealed that non-responders harbored a persistent population of CD34+ leukemic cells expressing high levels of HGF. However, all the peripheral blood cell populations lacked detectable expression of the HGF receptor, MET. Similarly, MET expression in publicly-available AML expression databases is low to undetectable. This observation led to our hypothesis that an unsampled bone marrow resident cell type expresses MET, responds to AML-derived HGF, and mediates treatment resistance.

To test this hypothesis, we developed a transgenic zebrafish model in which the zebrafish ortholog of HGF (hgfa) is aberrantly expressed in HSPCs, driven by the highly specific Runx1+23 enhancer. Overexpression of hgfa increased HSPC numbers in 72 hour-post-fertilization (hpf) embryos (control=2.47±0.42, hgfa=4.69±0.64; p=5.5e-3). Analysis by scRNA-seq revealed significant expansion of lepr+ mesenchymal stromal cells (MSCs) in Runx1:hgfa transgenic animals compared with controls. There was exclusive expression of met in the MSC cluster, consistent with this expansion being a direct consequence of hgfa signaling.

These in vivo findings were orthogonally validated using the human bone marrow stromal cell line, HS27a, which expresses the MET receptor at a transcript level >4 orders of magnitude higher than in AML cell lines OCIAML2, KG1a, and MOLM13 (log2 FC=14.55; p=2.3e-4). HS27a cells treated with 100ng HGF for 72 hours displayed a 2.4-fold increase in cell growth relative to baseline, while untreated cells grew only 1.8-fold (p=3.1e-2). CFU assays demonstrated an increase in mean colony area (p=6.2e-2) with HGF. Treatment with the MET inhibitor crizotinib decreased HS27a growth in a dose-dependent manner. Bulk RNA-seq of cells treated with HGF compared to untreated cells demonstrated that the HGF-specific gene signature in HS27a aligns with the zebrafish hgfa gene signature in MSCs (p=e-4).

Expression profiling in the zebrafish model revealed MSCs to be the dominant producers of ECM collagen, decorin, and cxcl8 (secreted factors known to regulate HSPC cell division, autophagy, and anchor HSPCs in the niche). Transcriptional heterogeneity was identified within HSC and HSPC compartments according to the presence of the Runx1:hgfa transgene. The transcriptional state preferentially occupied by HSCs and HSPCs from Runx1:hgfa embryos showed enrichment of actin filament-based processes (p=8.6e-18), cytoskeletal organization (p=4.9e-16), and GTPase signaling (p=1e-30). GSEA analysis further revealed enrichment of macroautophagy gene sets in HSCs in the Runx1:hgfa-preferred state.

We assessed the impact of autophagy on HSPC numbers in the Runx1:hgfa model using rapamycin and chloroquine, an inducer and inhibitor of autophagy, respectively. Autophagy inhibition with chloroquine reduced HSPC numbers in transgenic embryos, resulting in levels that were not significantly different from controls. Induction of autophagy with rapamycin increased HSPC numbers in both Runx1:hgfa(+) embryos and control clutchmates. However, the effect of rapamycin was greater in controls, suggesting that hgfa itself may increase HSPC numbers through autophagy induction (control=2.48±2.67, control+rapamycin=9.64±8.41; p=2.5e-11; hgfa(+)=4.21±5.05, hgfa(+)+rapamycin=9.93±7.55; p=3.98e-7).

To assess the long-term impacts of aberrant hgfa expression on HSPCs, we performed scRNA-seq on adult zebrafish at 9 months post-fertilization and found a reduction in HSCs with an increase in fibrotic elements in Runx1:hgfa transgenics compared to controls. HSC lineage tracing using the GESTALT barcoding system showed no change in clonality in transgenics compared to control.

These findings support a model in which HGF remodels the hematopoietic microenvironment and activates autophagy via MSCs, which in turn may promote AML drug resistance by preserving replicative capacity. Long-term, aberrant HGF expression appears to favor MSC expansion and marrow fibrosis in the absence of leukemia. Ongoing work seeks to identify mechanisms by which MSC-derived secreted factors promote drug resistance in AML.

Annika Chura, MS: No relevant conflicts of interest to declare.